Annals of Oncology

news
Stay out of the hospital! Wherever you are in the world...
pp. 495-498(4)

Profiling: “Editorial on ‘Survival after progression in patients with follicular lymphoma: analysis of prognostic factors’ ”, by S. Montoto et al. (Ann Oncol 2002; 13: 523–530)
pp. 499-500(2)
Author: McLaughlin P.

Inhibition of bcl-2 as cancer therapy
pp. 501-502(2)
Authors: Ciardiello F.; Tortora G.

Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review
pp. 503-512(10)
Authors: Kremer L.C.M.; van Dalen E.C.; Offringa M.; Voûte P.A.

Raltitrexed: current clinical status and future directions
pp. 513-522(10)
Authors: Van Cutsem E.; Cunningham D.; Maroun J.; Cervantes A.; Glimelius B.

Survival after progression in patients with follicular lymphoma: analysis of prognostic factors
pp. 523-530(8)
Authors: Cobo F.; Montoto S.; Colomer D.; López-Guillermo A.; Campo E.; Ferrer A.; Montserrat E.; Camós M.; Álvarez-Larrán A.; Bosch F.; Bladé J.; Cervantes F.; Esteve J.

Relevance of intraocular involvement in the management of primary central nervous system lymphomas
pp. 531-538(8)
Authors: Chassagne C.; Ferreri A.J.M.; Tinguely M.; Blay J.-Y.; Borisch B.; Reni M.; Berger F.; Pasini F.; Ponzoni M.; Gubkin A.; Cavalli F.; Tirelli U.; Calderoni A.; Zucca E.; Cortelazzo S.

A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer
pp. 539-545(7)
Authors: Rudin C.M.; Otterson G.A.; Mauer A.M.; Villalona-Calero M.A.; Tomek R.; Prange B.; George C.M.; Szeto L.; Vokes E.E.

Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer
pp. 546-552(7)
Authors: Canavese G.; Venturini M.; Rosso R.; Del Mastro L.; Garrone O.; Angiolini C.; Merlano M.; Bergaglio M.; Tolino G.; Lambiase A.; Baldini A.

Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study
pp. 553-557(5)
Authors: Mailliard J.A.; Alberts S.R.; Townley P.M.; Sargent D.J.; Goldberg R.M.; Cha S.S.; Moore D.F.; Krook J.E.; Pitot H.C.; Fitch T.R.; Wiesenfeld M.

Capecitabine (Xeloda^®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors
pp. 558-565(8)
Authors: Díaz-Rubio E.; Evans T.R.J.; Tabernero J.; Cassidy J.; Sastre J.; Eatock M.; Bisset D.; Regueiro P.; Baselga J.

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
pp. 566-575(10)
Authors: Graeven U.; Cassidy J.; McKendrick J.; Twelves C.; Maroun J.; Van Cutsem E.; Marshall J.; Hoff P.; Osterwalder B.; Bajetta E.; Pérez-Manga G.; Boyer M.; Rosso R.; Bugat R.; Rougier P.; Burger U.; Schilsky R.L.; Garin A.

Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma
pp. 576-581(6)
Authors: Hohneker J.; Benson III A.B.; Mitchell E.; Abramson N.; Klencke B.; Ritch P.; Burnham J.P.; McGuirt C.; Bonny T.; Levin J.

Low-dose trimetrexate glucuronate and protracted 5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer
pp. 582-588(7)
Authors: Amado R.G.; Rosen L.S.; Hecht J.R.; Lin L.-S.; Rosen P.J.

Determinants of chronic fatigue in disease-free breast cancer patients: a cross-sectional study
pp. 589-598(10)
Authors: Servaes P.; Verhagen S.; Bleijenberg G.

High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis
pp. 599-605(7)
Authors: Beyer J.; Stenning S.; Gerl A.; Fossa S.; Siegert W.

A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon -2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population
pp. 606-613(8)
Authors: Clark J.I.; Kuzel T.M.; Lestingi T.M.; Fisher S.G.; Sorokin P.; Martone B.; Viola M.; Sosman J.A.

Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours
pp. 614-621(8)
Authors: Vitali M.; Bajetta E.; Ferrari L.; Beretta E.; Seregni E.; Procopio G.; Bombardieri E.; Catena L.; Ferrario E.; Martinetti A.; Di Bartolomeo M.; Buzzoni R.; Celio L.

Audiotapes of oncology consultations: only for the first consultation?
pp. 622-627(6)
Authors: Knox R.; Butow P.N.; Devine R.; Tattersall M.H.N.

Acute transient encephalopathy after paclitaxel infusion: report of three cases
pp. 629-631(3)
Authors: Ziske C.G.; Schöttker B.; Gorschlüter M.; Mey U.; Kleinschmidt R.; Schlegel U.; Sauerbruch T.; Schmidt-Wolf I.G.H.

The chemotherapy of metastatic gastric adenocarcinomas with hypersecretion of -fetoprotein or -human chorionic gonadotrophin: report of two cases
pp. 632-636(5)
Authors: Germann N.; Gross-Goupil M.; Wasserman E.; Emile J.-F.; Misset J.-L.; Reynes M.; Goldwasser F.

Unusual presentation of Hodgkin’s lymphoma
pp. 637-a-638(2)
Authors: Knibbeler-van Rossum C.T.A.M.; Peters F.J.P.; Erdkamp F.L.G.; Bos L.P.

Comment on “Perhaps not everyone knows that...”, (Ann Oncol 2001; 12: 1186)
pp. 637-637(1)
Authors: Sulkes A.; Schlachter J.

W.B. Coleman & G.J. Tsongalis (eds). The Molecular Basis of Human Cancer
pp. 639-a-639-a(1)
Author: Kerr D.J.

S.P. Ethier (ed). Endocrine Oncology
pp. 639-639(1)
Author: Spataro V.